Predict your next investment

Venture Capital
FINANCIAL | Investment Firms & Funds
lspvc.com

See what CB Insights has to offer

Investments

192

Portfolio Exits

50

Funds

13

Partners & Customers

1

Service Providers

1

About Life Sciences Partners

Life Sciences Partners is a venture capital firm specializing in early- to mid-stage life sciences companies.

Life Sciences Partners Headquarter Location

Johannes Vermeerplein 9

Amsterdam, 1071 DV,

Netherlands

31 20 664 5500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Life Sciences Partners Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Life Sciences Partners Rank

Research containing Life Sciences Partners

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Life Sciences Partners in 1 CB Insights research brief, most recently on May 23, 2019.

Latest Life Sciences Partners News

EQT to acquire LSP

Nov 10, 2021

EQT is to acquire LSP (Life Sciences Partners), a European life sciences venture capital firm with approximately EUR2.2 billion of assets under management (AUM) and a team of 34 professionals. LSP, headquartered in Amsterdam, the Netherlands, is a venture capital firm that invests in innovative companies with strong scientific and clinical rationale across several life sciences strategies. The Company was founded in 1998 and today is one of Europe’s largest and most experienced life sciences investment firms. LSP employs 34 professionals across its offices in Amsterdam, Munich, and Boston. Over the past two decades, LSP has invested in over 150 life sciences companies, generated strong returns, and built a top-performing life sciences franchise. As part of EQT, the LSP team will be able to continue to operate in the same successful manner as they have been operating over the past two decades. The entire LSP team, including all partners and employees, will join EQT. LSP is expected to generate approximately EUR37 million in revenues and approximately EUR24 million in EBITDA (excluding carried interest) during 2021. The proposed consideration is expected to equate to a mid-teens EBITDA multiple on a run-rate basis at completion. Per Franzén, Partner and Head of EQT Private Capital, says: “EQT has a long history of developing strong healthcare companies, and today we are one of the largest and most active private equity investors in the sector globally. Integrating LSP within EQT’s Private Capital platform will bring compelling cross-pollination opportunities for our other strategies and complement our sector expertise – making EQT an even better and more innovative healthcare investor.”   René Kuijten, Managing Partner at LSP, and incoming Partner and Head of EQT Life Sciences, says: “’Europe has many attractive life sciences companies. Together with EQT, one of the largest European private equity firms with more than EUR70 billion under management, LSP can select, develop, and finance these opportunities even better than before. Given the strong cultural fit and the complementarity between our organisations, we are convinced that joining forces is a win-win for our investors, our portfolio companies, our LSP colleagues, and the broader European life sciences ecosystem.”   Martijn Kleijwegt, Founder and Managing Partner at LSP, adds: “The partnership with EQT not only accelerates LSP’s growth opportunities in an unprecedented way but also guarantees the long-term continuity of LSP’s active role in the life sciences industry in Europe and beyond. Having started the firm in 1998, I feel proud to have built the firm with all the partners and other colleagues, and I feel very good about where it has landed today.”   Michael Bauer, Partner and Co-Head of EQT's Global Healthcare sector team, says: “We are truly excited about the opportunity to join forces with LSP and form EQT Life Sciences. The EQT and LSP teams have complementary skill sets, and the combination will allow us to support healthcare companies and their management teams in a unique way. The life science industry is going through a phase of unprecedented innovation and, through the partnership with LSP, EQT will be able to participate in this growth opportunity and open up doors for attractive new investments in the space.”

Life Sciences Partners Investments

192 Investments

Life Sciences Partners has made 192 investments. Their latest investment was in ViCentra as part of their Series C on December 12, 2021.

CBI Logo

Life Sciences Partners Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

12/16/2021

Series C

ViCentra

$74M

No

11

12/2/2021

Series A

AviadoBio

$80M

Yes

6

11/29/2021

Series C

HotSpot Therapeutics

$100M

Yes

8

10/26/2021

Series C

Subscribe to see more

$99M

Subscribe to see more

10

10/14/2021

Series A - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

12/16/2021

12/2/2021

11/29/2021

10/26/2021

10/14/2021

Round

Series C

Series A

Series C

Series C

Series A - II

Company

ViCentra

AviadoBio

HotSpot Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$74M

$80M

$100M

$99M

$99M

New?

No

Yes

Yes

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

11

6

8

10

10

Life Sciences Partners Portfolio Exits

50 Portfolio Exits

Life Sciences Partners has 50 portfolio exits. Their latest portfolio exit was ONWARD on October 21, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

10/21/2021

IPO

$99M

3

2/24/2021

Acquired

$99M

4

2/5/2021

IPO

1

1/4/2021

Acquired

Subscribe to see more

$99M

Subscribe to see more

10

7/10/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/21/2021

2/24/2021

2/5/2021

1/4/2021

7/10/2020

Exit

IPO

Acquired

IPO

Acquired

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

3

4

1

10

10

Life Sciences Partners Fund History

13 Fund Histories

Life Sciences Partners has 13 funds, including LSP 7.

Closing Date

Fund

Fund Type

Status

Amount

Sources

11/4/2021

LSP 7

$0.96M

1

3/10/2020

LSP 6

Multi-Stage Venture Capital

Closed

$600M

2

12/12/2017

LSP Health Economics Fund II

Late-Stage Venture Capital

Closed

$330M

2

6/2/2016

Life Sciences Partners V

Subscribe to see more

Subscribe to see more

$99M

10

3/10/2014

Health Economics Fund

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

11/4/2021

3/10/2020

12/12/2017

6/2/2016

3/10/2014

Fund

LSP 7

LSP 6

LSP Health Economics Fund II

Life Sciences Partners V

Health Economics Fund

Fund Type

Multi-Stage Venture Capital

Late-Stage Venture Capital

Subscribe to see more

Subscribe to see more

Status

Closed

Closed

Subscribe to see more

Subscribe to see more

Amount

$0.96M

$600M

$330M

$99M

$99M

Sources

1

2

2

10

10

Life Sciences Partners Partners & Customers

1 Partners and customers

Life Sciences Partners has 1 strategic partners and customers. Life Sciences Partners recently partnered with Bristol-Myers Squibb on November 11, 2015.

Date

Type

Business Partner

Country

News Snippet

Sources

11/24/2015

Partner

Bristol-Myers Squibb

United States

LSP, Bristol-Myers Squibb announce immuno-oncology collaboration

LSP , the specialist healthcare investment firm , has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need .

1

Date

11/24/2015

Type

Partner

Business Partner

Bristol-Myers Squibb

Country

United States

News Snippet

LSP, Bristol-Myers Squibb announce immuno-oncology collaboration

LSP , the specialist healthcare investment firm , has announced today a strategic collaboration with Bristol-Myers Squibb Company in which the companies will work closely together in identifying European breakthrough technologies and products in immuno-oncology and other areas of unmet medical need .

Sources

1

Life Sciences Partners Service Providers

1 Service Provider

Life Sciences Partners has 1 service provider relationship

Service Provider

Associated Rounds

Provider Type

Service Type

Series A

Counsel

General Counsel

Service Provider

Associated Rounds

Series A

Provider Type

Counsel

Service Type

General Counsel

Partnership data by VentureSource

Life Sciences Partners Team

17 Team Members

Life Sciences Partners has 17 team members, including current Founder, Owner, Martijn Keijwegt.

Name

Work History

Title

Status

Martijn Keijwegt

Founder, Owner

Current

Onno Stolpe

Chief Executive Officer

Current

Merijn Klaassen

Chief Financial Officer

Current

Koen Sintnicolaas

Controller

Current

Rudy Dekeyser

Managing Partner

Current

Name

Martijn Keijwegt

Onno Stolpe

Merijn Klaassen

Koen Sintnicolaas

Rudy Dekeyser

Work History

Title

Founder, Owner

Chief Executive Officer

Chief Financial Officer

Controller

Managing Partner

Status

Current

Current

Current

Current

Current

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.